Recruiting

Testing a new cancer drug for advanced solid tumors

Plain-English translation of NCT06666270 on ClinicalTrials.gov ↗ · Source last updated July 2025 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

This is one of the first times this treatment has been tested in people.

What is this trial?

This is a Phase I clinical trial testing a new drug called , which works by blocking a protein that some cancer cells use to repair DNA damage. Researchers want to understand how safe this medication is, how your body processes it, and whether it can slow or shrink advanced cancers — especially in people whose tumors have certain genetic changes related to DNA repair.

Standard cancer treatments don't work for everyone, and some patients run out of options. This medication targets a specific weakness in cancer cells that have difficulty repairing DNA, offering hope for people with advanced cancers that have stopped responding to other therapies.

Do you qualify?

You likely qualify if…

you are 18 years or older
you have been diagnosed with advanced or metastatic breast, ovarian, prostate, or other solid tumors that have stopped responding to standard treatments
your cancer has certain genetic changes (BRCA mutations or other DNA repair deficiencies) that can be detected through blood or tissue testing
you have at least one measurable tumor that can be seen on imaging
you are in good enough health overall (with a life expectancy of at least 12 weeks and an ECOG performance score of 0 or 1)
your heart, lungs, liver, and kidneys are working well enough to tolerate the study drug

You likely don't qualify if…

you have cancer that has spread to your brain or the lining of your brain with active symptoms
you have had other cancers in the past 5 years (except for certain skin cancers or early-stage cancers that were completely cured)
you have had serious surgery or trauma in the past 4 weeks before starting the study
you are currently taking certain medications that would interfere with how your body processes this drug
you have severe nausea, difficulty swallowing, or conditions like Crohn's disease that prevent your body from absorbing oral medications

What participation looks like

You will take tablets by mouth daily, as an outpatient. You'll visit the research clinic regularly for blood tests, physical exams, and imaging scans to monitor how you're responding and check for side effects. Before you start, researchers will take a sample of your tumor tissue or blood to test for the genetic changes this medication targets. The study is designed to enroll about 30 patients, and your participation will help doctors understand whether this new treatment is safe and effective.

AI-generated summary from trial data · Jun 18, 2026 · Not medical advice

Trial locations(2 sites)

China

Henan Cancer Hospital, Zhengzhou, Henan

Fudan University Shanghai Cancer Center., Shanghai, Shanghai Municipality